미국 · 보도자료 · STOK · 2026-10-05 11:00
드라베증후군 신약 조레부너센, 美 FDA 미팅 완료…NDA 궤도 진입
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced the completion of a successf
